A Phase 1 Ethnobridging TriaL of AGA2118 in Healthy Japanese, Chinese, and Caucasian ParticipantS (ATLAS)

This study tests a new drug called AGA2118 in healthy volunteers from three ethnic backgrounds — Japanese, Chinese, and Caucasian — to see whether the drug behaves the same way in people from different ethnic groups. This is known as an ethnobridging study. **You may be eligible if...** - You are a healthy man or woman between 18 and 65 years old - You meet the ethnic criteria for Japanese, Chinese, or Caucasian ancestry - Your vitamin D level is adequate (25-hydroxyvitamin D at least 30 ng/mL) - You are willing to take calcium and vitamin D supplements during the study **You may NOT be eligible if...** - You have participated in another clinical trial in the past 6 months - You had a bone fracture in the past 6 months - You had a heart attack or stroke in the past 12 months - You have had cancer in the past 5 years - You currently have abnormal calcium levels in your blood - You are pregnant, breastfeeding, or planning to become pregnant during the study Talk to your doctor to see if this trial is right for you.